Cargando…

Controlled drug release for inflammatory bowel disease (IBD)

Controlled drug release in formulation is an important area of research. Formulations using crospovidone as super-disintegrants to achieve immediate release once it reaches the ileo- cecal region is relevant. The Eudragit L30D pH dependent polymer that allows drug release after a lag time of 4-5 hrs...

Descripción completa

Detalles Bibliográficos
Autores principales: Asha, D, Jeganath, S, Bupesh, G, Sahoo, UK, Bhaskar, M, Pandian, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505240/
https://www.ncbi.nlm.nih.gov/pubmed/32994676
http://dx.doi.org/10.6026/97320630016513
_version_ 1783584768407896064
author Asha, D
Jeganath, S
Bupesh, G
Sahoo, UK
Bhaskar, M
Pandian, K
author_facet Asha, D
Jeganath, S
Bupesh, G
Sahoo, UK
Bhaskar, M
Pandian, K
author_sort Asha, D
collection PubMed
description Controlled drug release in formulation is an important area of research. Formulations using crospovidone as super-disintegrants to achieve immediate release once it reaches the ileo- cecal region is relevant. The Eudragit L30D pH dependent polymer that allows drug release after a lag time of 4-5 hrs to achieve desired drug release from the drug delivery system is critical. Hence, pre-formulation to study drug-polymer interaction is essential. The linear correlation between the predicted and actual values for all the batches of optimization is shown with high correlation coefficient (r-value). Therefore, the designed formulation is promising for ileo-cecal targeted pulsatile drug delivery system in the management of Crohn's disease.
format Online
Article
Text
id pubmed-7505240
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Biomedical Informatics
record_format MEDLINE/PubMed
spelling pubmed-75052402020-09-28 Controlled drug release for inflammatory bowel disease (IBD) Asha, D Jeganath, S Bupesh, G Sahoo, UK Bhaskar, M Pandian, K Bioinformation Research-Article Controlled drug release in formulation is an important area of research. Formulations using crospovidone as super-disintegrants to achieve immediate release once it reaches the ileo- cecal region is relevant. The Eudragit L30D pH dependent polymer that allows drug release after a lag time of 4-5 hrs to achieve desired drug release from the drug delivery system is critical. Hence, pre-formulation to study drug-polymer interaction is essential. The linear correlation between the predicted and actual values for all the batches of optimization is shown with high correlation coefficient (r-value). Therefore, the designed formulation is promising for ileo-cecal targeted pulsatile drug delivery system in the management of Crohn's disease. Biomedical Informatics 2020-07-31 /pmc/articles/PMC7505240/ /pubmed/32994676 http://dx.doi.org/10.6026/97320630016513 Text en © 2020 Biomedical Informatics http://creativecommons.org/licenses/by/3.0/ This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
spellingShingle Research-Article
Asha, D
Jeganath, S
Bupesh, G
Sahoo, UK
Bhaskar, M
Pandian, K
Controlled drug release for inflammatory bowel disease (IBD)
title Controlled drug release for inflammatory bowel disease (IBD)
title_full Controlled drug release for inflammatory bowel disease (IBD)
title_fullStr Controlled drug release for inflammatory bowel disease (IBD)
title_full_unstemmed Controlled drug release for inflammatory bowel disease (IBD)
title_short Controlled drug release for inflammatory bowel disease (IBD)
title_sort controlled drug release for inflammatory bowel disease (ibd)
topic Research-Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505240/
https://www.ncbi.nlm.nih.gov/pubmed/32994676
http://dx.doi.org/10.6026/97320630016513
work_keys_str_mv AT ashad controlleddrugreleaseforinflammatoryboweldiseaseibd
AT jeganaths controlleddrugreleaseforinflammatoryboweldiseaseibd
AT bupeshg controlleddrugreleaseforinflammatoryboweldiseaseibd
AT sahoouk controlleddrugreleaseforinflammatoryboweldiseaseibd
AT bhaskarm controlleddrugreleaseforinflammatoryboweldiseaseibd
AT pandiank controlleddrugreleaseforinflammatoryboweldiseaseibd